Full Title
An Open-Label, Phase 1/1b, Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate CancerPurpose
In this study, researchers want to find the highest dose of the investigational drug ORIC-944 that can be given safely in people with metastatic prostate cancer that continues to grow despite standard treatments. ORIC-944 works by blocking a group of proteins called PRC2, which promote prostate cancer growth. It is taken orally (by mouth).
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Wassim Abida at 646-422-4633.
Protocol
22-181
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT05413421
ClinicalTrials.gov